View Older Stories View More Recent Stories

Feb 9, 2023 04:00PM AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE
Feb 2, 2023 09:01AM AstraZeneca (AZN) announces TEZSPIRE approved for self-administration in the US with a new pre-filled pen
Feb 2, 2023 09:00AM TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN
Jan 31, 2023 04:01PM AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Jan 31, 2023 06:03AM Amgen (AMGN) Announces Amjevita now Available in the US
Jan 31, 2023 06:00AM AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Jan 26, 2023 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Jan 6, 2023 04:00PM AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET
Jan 4, 2023 04:00PM AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Dec 20, 2022 07:30AM Arrowhead (ARWR) Receives $25M Milestone Payment from Amgen (AMGN)
Dec 20, 2022 07:30AM Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Dec 13, 2022 04:01PM Amgen (AMGN) Says Blincyto Added To Consolidation Chemotherapy Significantly Improves Survival In Adult Patients With Measurable Residual Disease-negative B-ALL
Dec 13, 2022 04:00PM BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Dec 12, 2022 07:50PM AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND
Dec 12, 2022 06:05AM AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS
Dec 1, 2022 09:31AM Amgen (AMGN) Resents New AMG 133 Phase 1 Clinical Data At WCIRDC 2022
Dec 1, 2022 09:30AM AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022
Nov 28, 2022 04:00PM AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022
Nov 23, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE
Nov 7, 2022 04:16PM Amgen (AMGN) Presents New Repatha Data
Nov 7, 2022 04:16PM AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022
Nov 7, 2022 09:00AM AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022
Nov 7, 2022 05:42AM Amgen (AMGN) Reports New Phase 2 Data of olpasiran
Nov 6, 2022 06:13PM AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS
Nov 4, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 CREDIT SUISSE GLOBAL HEALTHCARE CONFERENCE
Nov 3, 2022 04:01PM AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
Nov 2, 2022 04:00PM AMGEN TO WEBCAST INVESTOR CALL AT AHA 2022
Oct 31, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 THIRD QUARTER FINANCIAL RESULTS
Oct 28, 2022 04:00PM AMGEN ANNOUNCES 2022 FOURTH QUARTER DIVIDEND
Oct 20, 2022 09:06AM Amgen (AMGN) Completes Acquisition of ChemoCentryx (CCXI)
Oct 20, 2022 09:05AM AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Oct 12, 2022 09:00AM AMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS
Oct 6, 2022 09:00AM AMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA
Sep 12, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Sep 12, 2022 05:36AM Amgen (AMGN) Reports Positive Phase 3 Data from CodeBreaK 200 Trial
Sep 12, 2022 05:34AM Amgen (AMGN) Reports LUMAKRAS plus VECTIBIX Confirmed 30% ORR
Sep 12, 2022 04:25AM LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Sep 11, 2022 06:05PM LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Sep 8, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
Sep 8, 2022 08:17AM Amgen (AMGN) Announces Positive New Data At Eadv 2022 For Otezla
Sep 8, 2022 08:15AM AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
Sep 7, 2022 04:00PM AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022
Sep 2, 2022 04:05PM AMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE
Sep 2, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE
Aug 30, 2022 04:04PM Amgen (AMGN) Reports Phase 3 CodeBreaK 200 trial of Lumakras Met Primary Endpoint
Aug 30, 2022 04:03PM AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Aug 30, 2022 09:00AM AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022
Aug 29, 2022 03:10AM NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
Aug 23, 2022 09:02AM Amgen (AMGN) Announces Positive Phase 3 Study of Biosimilar Candidate to SOLIRIS
Aug 23, 2022 09:00AM AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
View More Recent Stories View Older Stories